Retatrutide (30 mg Vial) Dosage Protocol

Quickstart Highlights

Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors^[1], studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes^[2]^[3]. With an extended half-life of approximately 6 days, this peptide enables convenient once-weekly subcutaneous dosing with a gradual titration protocol to optimize tolerability^[1]^[4].

Reconstitute: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration for convenient weekly dosing.
Typical weekly range: 2–12 mg once weekly (gradual escalation over 12+ weeks).
Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.

Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing

Standard / Gradual Titration Approach (3 mL = 10.0 mg/mL)

Week(s)	Weekly Dose (mcg) (mg)	Units (per injection) (mL)
Weeks 1–4	2,000 mcg (2 mg)	20 units (0.20 mL)
Weeks 5–8	4,000 mcg (4 mg)	40 units (0.40 mL)
Weeks 9–12	8,000 mcg (8 mg)	80 units (0.80 mL)
Weeks 13+	12,000 mcg (12 mg)	120 units (1.20 mL) — split into 2 injections or use 2 vials

Frequency: Inject once weekly subcutaneously. This schedule follows clinical trial protocols that demonstrated significant weight loss (up to 24% at 48 weeks with 12 mg weekly)^[2] while minimizing gastrointestinal adverse events through gradual escalation^[1]^[4]. Starting at 2 mg weekly (versus 4 mg) significantly reduces initial GI side effects. The 30 mg vial size with 3.0 mL reconstitution provides excellent concentration (10.0 mg/mL) for convenient measuring. For the maintenance dose (12 mg = 1.20 mL), either split into two 0.60 mL injections at different sites or reconstitute an additional vial.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake vigorously).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Note: The 30 mg vial size is highly efficient for weekly protocols. With 10.0 mg/mL concentration, lower doses (2–8 mg) fit comfortably in a single syringe, while the maintenance dose (12 mg) requires either splitting across two injection sites or using a second vial for the remaining 0.20 mL (2 mg).

Supplies Needed

Plan based on a 12–48 week weekly protocol with gradual titration to maintenance dose.

Peptide Vials (Retatrutide, 30 mg each): Highly efficient vial size—minimal waste
- 12 weeks (2→4→8 mg titration): 2 vials
- 24 weeks (up to 12 mg): 7 vials
- 48 weeks (maintenance at 12 mg): 17 vials
Insulin Syringes (U-100, 1 mL):
- Per week: 1 syringe (once-weekly dosing)
- 12 weeks: 12 syringes
- 24 weeks: 24 syringes
- 48 weeks: 48 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 24 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- 48 weeks (17 vials): 51 mL → 6 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 12 weeks: 24 swabs → 1 × 100-count box
- 24 weeks: 48 swabs → 1 × 100-count box
- 48 weeks: 96 swabs → 1 × 100-count box

Protocol Overview

Concise summary of the once-weekly regimen based on clinical trial protocols.

Goal: Achieve substantial weight loss (up to 24% of body weight) and improved metabolic parameters through triple receptor agonism^[2]^[5].
Schedule: Weekly subcutaneous injections for 12+ weeks with gradual dose escalation.
Dose Range: 2–12 mg once weekly; clinical trials tested up to 12 mg as the maximum maintenance dose^[1]^[3].
Reconstitution: 3.0 mL per 30 mg vial (10.0 mg/mL) provides optimal concentration with minimal waste—the most efficient vial size available.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.